CORT Trading Analysis - 11/10/2026 02:55 PM — TRU-SENTIMENT

CORT (Corcept Therapeutics Inc.) at $71.90. True Sentiment Bullish, delta 40-60 call 95% / put 5%, call $4,999,900 vs put $253,760. RSI 8.5.

TRU-SENTIMENT · DeltaNeutral

CORT Trading Analysis - 11/10/2026 02:55 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

CORT (Corcept Therapeutics Inc.) at $71.90. True Sentiment Bullish, delta 40-60 call 95% / put 5%, call $4,999,900 vs put $253,760. RSI 8.5.

Symbol
CORT
Price
$71.90
Article bias (separate from True Sentiment)
bullish
Conviction
low
Published
2026-11-10 14:55:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options):

Options flow (Delta 40-60 only): Call $4,999,900 (95.2%), Put $253,760 (4.8%), Sentiment Bullish. Contracts: 5,514 calls vs 208 puts. 10 call trades, 1 put trade.

Conviction: Extreme call-leaning directional bet despite price near 52-week low-third. Divergence: technicals bearish/oversold, sentiment bullish — matches option-spread engine "divergence detected" note.

Key Statistics: CORT

$71.92 -3.19%
52-Week Range
$28.66 - $126.38
Market Cap
$7.87B
P/E (TTM)
48.20
PEG Ratio
N/A
Beta
0.34
Next Earnings
N/A
Avg Volume
$664,043
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)48.20
EPS (trailing 12 mo)$1.51
Market cap$7.87B
Shares outstanding109.4M

Dividend

Dividend yield0.00%

Risk & range

Beta0.34
52-week low$28.66
52-week high$126.38
Historical volatility80.8%

Ownership & trading

Institutional ownership39.3%
Average daily volume1.2M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context:

Corcept Therapeutics (CORT) has historically been a developer of cortisol-modulating therapies, with its lead product Korlym and pipeline candidates in oncology and metabolic disease often driving sentiment. Using general knowledge (not from embedded data), recent relevant context includes:

  • Positive Phase 2/3 data readouts for relacorilant in Cushing's syndrome and prostate cancer have previously acted as upside catalysts for CORT.
  • FDA-related developments or advisory panel outcomes for cortisol receptor antagonists remain key binary events that can sharply move the stock.
  • Biotech sector rotation and interest-rate sensitivity have pressured small/mid-cap pharma names, potentially contributing to broad weakness.
  • No confirmed imminent earnings date is known from this context, but seasonal catalysts (medical conferences) often surface in H2.

Contextually, the embedded data shows a severe drawdown from ~$122 to ~$74 over recent weeks, coinciding with extreme options bullishness — suggesting possible speculative repositioning or recovery bets despite weak price action.

Fundamental Analysis:

Based strictly on the provided FUNDAMENTALS data:

  • Trailing P/E: 48.20; Trailing EPS: $1.51 — valuation is elevated vs. broad market but typical for biotech with binary pipeline risk.
  • Market Cap: $7.87B; Shares Outstanding: 109,443,000; Dividend Yield: 0.00% (no income).
  • Beta: 0.34 (low systemic risk); 52-Week Range: $28.66 – $126.38 (current ~$74 is near lower third).
  • Institutional Ownership: 39.31% — moderate; Average Volume: 1,223,000.
  • Historical Volatility: 80.85% — very high realized vol.
  • Missing fields: Revenue Growth, Margins, ROE, D/E, FCF, PEG, Forward PE, Analyst Target — unavailable in data.

Fundamentals show a profitable-but-richly-valued biotech with low beta and no dividend. The steep price decline is not explained by provided fundamental deterioration, creating divergence from the bullish options sentiment.

Current Market Position:

Current price per indicators: $74.29 (as of 2026-11-09 close). Minute bars show 2026-11-09 open $73.31, low $70.51, close $74.29; 2026-11-10 intraday faded from $72.61 (14:05) to $71.90 (14:25) on rising volume (21,065).

Support
$70.51
Resistance
$76.58
Recent Close
$74.29
30d High
$122.81
30d Low
$70.51

Intraday momentum on 2026-11-10 is negative (lower highs/lows, volume expanding into weakness).

Technical Analysis:

Technical Indicators

RSI (14)
08.53
MACD
-10.74
Signal
-08.59
Hist
-02.15
SMA 5
76.17
SMA 20
94.40
SMA 50
106.91
BB Lower
61.13
BB Upper
127.66
ATR 14
06.45

Price is below all SMAs (bearish stack: 5 < 20 < 50). RSI 8.53 = deeply oversold. MACD negative and histogram worsening. Bollinger mid $94.40, price beneath lower band proximity ($61.13 lower). 30-day range $70.51–$122.81; price near bottom.

True Sentiment Analysis (Delta 40-60 Options):

Options flow (Delta 40-60 only): Call $4,999,900 (95.2%), Put $253,760 (4.8%), Sentiment Bullish. Contracts: 5,514 calls vs 208 puts. 10 call trades, 1 put trade.

Conviction: Extreme call-leaning directional bet despite price near 52-week low-third. Divergence: technicals bearish/oversold, sentiment bullish — matches option-spread engine "divergence detected" note.

Key Price Levels (observational only):

Support
$70.51
Resistance
$76.58
BB Lower
$61.13
SMA 5
$76.17
SMA 20
$94.40

Interactive charts load with JavaScript. This text is the crawlable summary.